Literature DB >> 18621624

Molecular epidemiology to better predict lung cancer risk.

Mary E Reid1, Regina Santella, Christine B Ambrosone.   

Abstract

Although it is clear that smoking causes lung cancer, it is not known why some smokers develop the disease while others do not. Little is also known regarding risk factors for lung cancer among never-smokers, particularly women, or why women with lung cancer are more likely to have a family history of cancer, to be diagnosed at a young age, or to have adenocarcinoma. The application of molecular epidemiology to the study of lung cancer risk might facilitate elucidation of these questions. In this review, the molecular epidemiology of lung cancer is discussed, with an emphasis on studies of genetic variability in metabolic pathways as a means for determining susceptibility. Work that has assessed intermediate markers of risk, such as DNA adducts, is also presented, as are studies of tumor tissue alterations, such as mutations and DNA methylation, in relation to risk of lung cancer. Finally, approaches to evaluating factors that might explain the differing epidemiology of lung cancer between men and women are also presented. It is likely that, by incorporating biomarkers of susceptibility, exposure, and effect, molecular epidemiologic approaches might better define factors that explain some of the variability in lung cancer risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621624      PMCID: PMC4459130          DOI: 10.3816/CLC.2008.n.022

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  56 in total

1.  Genetic susceptibility to lung cancer.

Authors:  York E Miller; Pamela Fain
Journal:  Semin Respir Crit Care Med       Date:  2003-04       Impact factor: 3.119

2.  Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.

Authors:  R Gealy; L Zhang; J M Siegfried; J D Luketich; P Keohavong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-04       Impact factor: 4.254

Review 3.  Is there a genetic basis for lung cancer susceptibility?

Authors:  C I Amos; W Xu; M R Spitz
Journal:  Recent Results Cancer Res       Date:  1999

4.  Gender difference in DNA adduct levels among nonsmoking lung cancer patients.

Authors:  Y W Cheng; L L Hsieh; P P Lin; C P Chen; C Y Chen; T S Lin; J M Su; H Lee
Journal:  Environ Mol Mutagen       Date:  2001       Impact factor: 3.216

5.  Lung cancer incidence in never smokers.

Authors:  Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

6.  Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

Authors:  M F Denissenko; A Pao; M Tang; G P Pfeifer
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

7.  Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.

Authors:  Daniele Campa; Shanbeh Zienolddiny; Valentina Maggini; Vidar Skaug; Aage Haugen; Federico Canzian
Journal:  Carcinogenesis       Date:  2003-11-06       Impact factor: 4.944

8.  Differences in lung cancer risk between men and women: examination of the evidence.

Authors:  E A Zang; E L Wynder
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies.

Authors:  Zheng Ye; Honglin Song; Julian P T Higgins; Paul Pharoah; John Danesh
Journal:  PLoS Med       Date:  2006-03-07       Impact factor: 11.069

View more
  6 in total

1.  Gender issues and the molecular epidemiology of lung cancer risk.

Authors:  Philip Lazarus
Journal:  Clin Lung Cancer       Date:  2008-05       Impact factor: 4.785

Review 2.  Better cancer biomarker discovery through better study design.

Authors:  Andrew Rundle; Habibul Ahsan; Paolo Vineis
Journal:  Eur J Clin Invest       Date:  2012-09-23       Impact factor: 4.686

3.  Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis.

Authors:  Therese H Nøst; Marit Holden; Tom Dønnem; Hege Bøvelstad; Charlotta Rylander; Eiliv Lund; Torkjel M Sandanger
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

4.  Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis.

Authors:  Thomas Blomquist; Erin L Crawford; D'Anna Mullins; Youngsook Yoon; Dawn-Alita Hernandez; Sadik Khuder; Patricia L Ruppel; Elizabeth Peters; David J Oldfield; Brad Austermiller; John C Anders; James C Willey
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 5.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

6.  DNA hypermethylation of the ZNF132 gene participates in the clinicopathological aggressiveness of 'pan-negative'-type lung adenocarcinomas.

Authors:  Kenichi Hamada; Ying Tian; Mao Fujimoto; Yoriko Takahashi; Takashi Kohno; Koji Tsuta; Shun-Ichi Watanabe; Teruhiko Yoshida; Hisao Asamura; Yae Kanai; Eri Arai
Journal:  Carcinogenesis       Date:  2021-02-25       Impact factor: 4.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.